In this setting, the TLR9 agonist converts the injected tumor into an in situ vaccine and the checkpoint provides the conditioning of uninjected tumor sites and protection from attenuation necessary for the mobilized T cells to mediate effective abscopal responses. Here, TLR9 is linked to neoplasm.